LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another milestone achieved on its U.S. Highway 93 go-to-market program – a strategic agreement with IQ Laser Vision, a leader in providing clear vision to clients with locations across California and Texas, and a top EVO ICL practice in North America..

加利福尼亚州森林湖——（商业新闻短讯）——STAAR Surgical Company（纳斯达克股票代码：STAA）是用于近视、散光和老视的EVO系列可植入Collamer®镜片（EVO ICL™）的领先开发商、制造商和销售商，今天宣布其在美国93号高速公路上市计划中取得的另一个里程碑，这是与IQ Laser Vision达成的战略协议，该公司是在加利福尼亚州和德克萨斯州为客户提供清晰视野的领军企业，也是EVO ICL在北美的顶级实践机构。。

IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering. IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months. To support the transition and ramp up, STAAR Surgical and IQ Laser Vision will collaborate on marketing, education, practice development and clinical support activities to further elevate awareness of EVO ICL and substantially increase the availability of the lenses to all qualified patients across the IQ Laser Vision Family of Practices, which includes Scott Hyver Visioncare, Ellis Eye, and Mattioli Vision Professionals..

IQ Laser Vision将使EVO ICL镜片成为寻求在-3D至-20D范围内进行手术视力矫正的患者的主要选择，作为其全面屈光功能的一部分。IQ Laser Vision计划在未来12个月内将其EVO ICL的体积增加近一倍。为了支持过渡和扩大规模，STAAR Surgical和IQ Laser Vision将在营销、教育、实践开发和临床支持活动方面进行合作，以进一步提高对EVO ICL的认识，并大幅提高IQ Laser Vision系列实践（包括Scott Hyver Visioncare、Ellis Eye和Mattioli Vision专业人员）中所有合格患者的镜片可用性。。

Tom Frinzi, Chair of the Board and CEO of STAAR Surgical, stated, “With the rapid growth of EVO ICL in the U.S., against the backdrop of a continued decline in laser vision correction procedures, it’s becoming clear that lens-based procedures like EVO ICL are the future of refractive vision correction.

STAAR Surgical董事会主席兼首席执行官汤姆·弗里茨（TomFrinzi）表示：“随着EVO ICL在美国的快速发展，在激光视力矫正程序持续下降的背景下，很明显，像EVO ICL这样的基于镜头的程序是屈光视力矫正的未来。

STAAR Surgical made a strategic pivot late last year to shape that future – with a program that works double-duty to accelerate growth in leading EVO-ready practices, while working alongside them to test, learn and invest in the strategic drivers of that growth. Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S.

去年年底，斯塔尔外科（STAAR Surgical）制定了一个战略支点，以塑造未来。该计划的双重职责是加速领先的EVO就绪实践的增长，同时与他们一起测试、学习和投资增长的战略驱动因素。今天，我们很高兴地宣布IQ Laser Vision已加入我们的美国。

Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far. Dr. Lin is a renowned leader and pioneer in refractive eye surgery having performed over 70,000 refractive procedures and is one of the most experienced ICL surgeons in North America, having implanted over 1,000 ICLs over the past 12 months.

93号公路项目，是迄今为止美国EVO ICL最大的协议。林博士是屈光手术领域的著名领导者和先驱，曾进行了70000多次屈光手术，是北美最有经验的ICL外科医生之一，在过去12个月内植入了1000多次ICL。

Dr. Lin’s deep and expansive expertise across refractive surgery makes his decision to offer EVO ICL as a primary option now all the more meaningful.”.

林博士在屈光手术方面拥有深厚而广泛的专业知识，因此他决定将EVO ICL作为主要选择，现在更有意义了。”。

Corneal laser-based refractive procedures, like LASIK and SMILE, work by removing corneal tissue to thin and reshape the cornea to correct a patient’s vision. EVO ICL is a lens-based refractive procedure, which works by implanting a lens in the eye to correct a patient’s vision while preserving the cornea.

基于角膜激光的屈光手术，如LASIK和SMILE，通过去除角膜组织使其变薄并重塑角膜来矫正患者的视力。EVO ICL是一种基于晶状体的屈光手术，它通过在眼睛中植入晶状体来矫正患者的视力，同时保留角膜。

Both lens and laser-based methods are safe and effective and have their place in a comprehensive refractive offering. EVO delivers excellent visual results across a broad range of correction with built-in UV protection and proven long-term stability. Further, EVO is a reversible lens implant, allowing surgeons to future-proof a patient’s eyes if age-related vision correction is needed down the road..

基于镜头和激光的方法都是安全有效的，在全面的屈光产品中占有一席之地。EVO通过内置紫外线防护和长期稳定性，在广泛的矫正范围内提供出色的视觉效果。此外，EVO是一种可逆的晶状体植入物，如果需要进行与年龄相关的视力矫正，外科医生可以在未来证明患者的眼睛。。

“At the IQ Laser Vision Family of Practices, our mission has always been to transform lives by delivering clear vision, and we are extremely grateful to have helped many patients including our own family members, celebrities, and athletes achieve that transformation,” said Robert T. Lin, MD, founder and surgeon, IQ Laser Vision.

IQ Laser Vision创始人兼外科医生Robert T.Lin医学博士说：“在IQ Laser Vision系列实践中，我们的使命始终是通过提供清晰的视力来改变生活，我们非常感谢帮助许多患者，包括我们自己的家庭成员、名人和运动员实现了这种转变。”。

“Refractive practices are at a critical juncture – with interest in corneal-based laser procedures waning, and contact lens- and eyeglass-wearers reluctant to commit to a more permanent solution – it’s time to consider a new path forward.”.

“屈光手术正处于关键时刻——人们对基于角膜的激光手术的兴趣正在减弱，隐形眼镜和眼镜佩戴者不愿意致力于更持久的解决方案——是时候考虑一条新的前进道路了。”。

Dr. Lin continued, “While studies show that refractive vision correction may be safer than long-term use of contact lenses, patients have been shying away from corneal-based laser vision correction (such as LASIK) due to a variety of factors. I believe EVO ICL is a way to re-invigorate the refractive surgery category as a whole.

林博士继续说：“虽然研究表明屈光矫正可能比长期使用隐形眼镜更安全，但由于各种因素，患者一直在回避基于角膜的激光视力矫正（如LASIK）。我相信EVO ICL是一种重新激活整个屈光手术类别的方法。

With surgeons across Europe and Asia using EVO ICL across the diopter range, and many offering ICL as the first-line treatment, it’s clear to me that we need to get the word out in the U.S. I am grateful to STAAR for recognizing this immense need, and working with us as we help patients achieve their dream of visual freedom.”.

欧洲和亚洲的外科医生在屈光度范围内使用EVO ICL，并且许多人提供ICL作为一线治疗，我很清楚，我们需要在美国宣传。我感谢斯塔尔认识到这一巨大需求，并与我们合作，帮助患者实现视觉自由的梦想。”。

For more information about EVO Implantable Collamer® Lenses, please visit https://evoicl.com.

有关EVO植入式Collamer®镜片的更多信息，请访问https://evoicl.com.

References

参考文献

EVO/EVO+ ICL DFU and PIB.

EVO/EVO+ICL DFU和PIB。

Martinez-Plaza E, Lopez-Miguel A, Lopez-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226: 117–125.

Martinez Plaza E，Lopez Miguel A，Lopez De La Rosa A，et al。EVO+Visian有晶状体植入胶原透镜对视觉表现以及视觉和生活质量的影响，Am J Ophthalmol 2021；226:117-125。

Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

Naves，J。Carracedo，G。Cacho-Babillo，I。二腺苷核苷酸测量作为LASIK和ICL手术后患者的干眼症评分。2012年在美国白内障和屈光手术学会（ASCRS）上发表。

About STAAR Surgical

关于STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision.

STAAR专门从事眼科手术已有40多年的历史，它设计、开发、制造和销售用于眼睛的植入式镜片。这些镜片旨在为患者提供视觉自由，减少或消除对眼镜或隐形眼镜的依赖。所有这些镜片都是可折叠的，这使得外科医生可以通过一个小切口将它们插入。

STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

用于屈光手术的STAAR晶状体被称为植入式Collamer®晶状体或“ICL”，其中包括EVO ICL™产品线。迄今为止，已售出300多万个ICL，STAAR在75多个国家销售这些镜片。要了解更多有关ICL的信息，请访问：EVOICL.com。该公司总部位于加利福尼亚州森林湖，在加利福尼亚州的Aliso Viejo、加利福尼亚州的蒙罗维亚和瑞士的Nidau经营制造和包装设施。

For more information, please visit the Company’s website at www.staar.com..

欲了解更多信息，请访问公司网站www.staar.com。。

About IQ Laser Vision

关于IQ激光视觉

Established in 1999 by Dr. Robert T. Lin, IQ Laser Vision is recognized as the most experienced EVO ICL and ZEISS SMILE vision correction center in North America. It has formed esteemed partnerships with Mattioli Vision Professionals, Scott Hyver Vision Care, and Ellis Eye by IQ Laser Vision, collectively known as the IQ Laser Vision Network.

IQ Laser Vision由Robert T.Lin博士于1999年成立，是北美经验最丰富的EVO ICL和蔡司微笑视力矫正中心。它与Mattioli Vision Professionals、ScottHyver Vision Care和Ellis Eye by IQ Laser Vision（统称IQ Laser Vision Network）建立了备受尊敬的合作伙伴关系。

These collaborations underscore its commitment to ophthalmological excellence. The team at IQ Laser Vision consists of board-certified surgeons with a collective experience exceeding 60 years, having successfully completed over 300,000 vision correction procedures. The clinic's state-of-the- art facilities are equipped with the latest eye care technology, including the advanced ArcScan Technology.

这些合作强调了其对眼科卓越的承诺。IQ Laser Vision的团队由经过董事会认证的外科医生组成，他们拥有超过60年的集体经验，成功完成了超过300000次视力矫正手术。该诊所最先进的设施配备了最新的眼部护理技术，包括先进的ArcScan技术。

With 18 locations across major U.S. cities including Los Angeles, Irvine, San Francisco, San Jose, and Houston, IQ Laser Vision ensures comprehensive accessibility to its services. For more information or to book a free consultation, please visit the company’s website at iqlaservision.com..

IQ Laser Vision在洛杉矶、欧文、旧金山、圣何塞和休斯顿等美国主要城市设有18个分店，确保其服务的全面可及性。欲了解更多信息或预订免费咨询，请访问公司网站iqlaservision.com。。

Important Safety Information for EVO ICL

EVO ICL的重要安全信息

The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before.

EVO Visian ICL镜片旨在矫正/减少-3.0 D至-20.0 D的近视，并治疗1.0 D至4.0 D的散光。如果您的近视在这些范围内，EVO Visian ICL手术可能会改善您的远视力，而无需眼镜或隐形眼镜。因为EVO Visian ICL可以校正远视，所以它并不能消除对阅读眼镜的需求，即使您以前从未戴过，您也可能会在某些时候需要它。

Since implantation of the EVO Visian ICL is a surgical procedure, before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery.

由于植入EVO Visian ICL是一种外科手术，因此在考虑EVO Visian ICL手术之前，您应该进行全面的眼部检查，并与您的眼科护理专业人员讨论EVO Visian ICL手术，特别是潜在的益处，风险和并发症。你应该讨论手术后愈合所需的时间。

Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts. You should NOT have EVO Visian ICL surgery if your doctor determines that 1) the shape of your eye is not appropriate, 2) you do not meet the minimum endothelial cell density for your age at the time of implantation, 3) you have moderate to severe glaucoma, 4) your vision is not stable; or 5) if you are pregnant or nursing..

并发症虽然很少见，但可能包括需要额外的外科手术，炎症，角膜后表面细胞的丢失，眼压升高和白内障。如果您的医生确定1）您的眼睛形状不合适，2）您在植入时不符合您年龄的最低内皮细胞密度，3）您患有中度至重度青光眼，4）您的视力不稳定；或5）如果你怀孕或哺乳。。

For additional information with potential benefits, risks and complications please visit evoicl.com.

有关潜在益处、风险和并发症的更多信息，请访问evoicl.com。

Safe Harbor

安全港

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2024 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the upcoming quarter, fiscal year 2024 and beyond.

所有非历史事实陈述的陈述均为前瞻性陈述，包括关于以下任何一项的陈述：2024年及以后的任何财务预测（包括销售）、计划、战略和管理目标，或实现这些计划的前景，对销售、收入、利润、费用或收益的预期，以及任何上述假设的任何陈述，包括与2024年及以后财政年度下一季度财务业绩有关的假设。

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 29, 2023 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events.

可能导致实际结果与此类前瞻性报表所示结果产生重大差异的重要因素包括与全球经济状况相关的风险和不确定性，以及公司截至2023年12月29日的年度报告中“风险因素”标题下的10-K表中列明的因素，该标题已向美国证券交易委员会备案，可在公司网站“投资者信息”部分的“SEC备案”标题下找到。我们不打算或有义务因新信息或事件而更新或修订任何财务预测或前瞻性报表。

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of COVID-19; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international trade disputes and substantial dependence on dem.

这些声明基于截至本新闻稿发布之日的预期和假设，并受到众多风险和不确定性的影响，这可能导致实际结果与前瞻性声明中描述的结果存在重大差异。风险和不确定性包括：全球经济状况；新型冠状病毒肺炎的影响；监管机构批准或拒绝现有、新的或改进的产品，或在批准之前或之后要求采取额外行动，或采取执法行动的自由裁量权；国际贸易争端和对dem的实质依赖。

We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts..

我们打算将我们的网站用作披露重大非公开信息的手段，并遵守FD法规规定的披露义务。此类披露将包含在我们网站的“投资者关系”部分。因此，投资者除了关注我们的新闻稿、SEC文件、公开电话会议和网络广播外，还应该监控我们网站的这些部分。。